Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · May 2020
The use of pancreatic enzyme replacement therapy in patients with a diagnosis of chronic pancreatitis and pancreatic cancer in the US is infrequent and inconsistent.
Patients with chronic pancreatitis or pancreatic cancer commonly develop exocrine pancreatic insufficiency, and may not be adequately treated with pancreatic enzyme replacement therapy (PERT). ⋯ Testing for exocrine insufficiency, and appropriate dosing of PERT in patients with chronic pancreatitis or pancreatic cancer, is infrequent and inconsistent in an insured US population. Efforts are needed to educate medical providers on the best practices for managing exocrine pancreatic insufficiency in these patients.
-
Aliment. Pharmacol. Ther. · May 2020
Observational StudyTofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
Tofacitinib is a Janus kinase inhibitor approved for the treatment of ulcerative colitis (UC). ⋯ Tofacitinib is an effective treatment for UC after anti-TNF and vedolizumab failure. However, a relatively high rate of adverse events was observed resulting in discontinuation in 6% of patients.
-
Aliment. Pharmacol. Ther. · Apr 2020
Meta AnalysisSystematic review with meta-analysis: Saccharomyces boulardii for treating acute gastroenteritis in children-a 2020 update.
There is still controversy with regard to the efficacy of individual probiotic strains for the management of acute gastroenteritis. ⋯ In children with acute gastroenteritis, low- to very low-quality evidence suggests that S boulardii confers a benefit for several diarrhoeal outcomes.